HomeNewsScreenerChartsMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

New Elite Feature: Chart Templates — Your indicators and design everywhere on Finviz

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

Fate Therapeutics, Inc.

Contributing Author

Recent Articles by Fate Therapeutics, Inc.

Apr-02
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) FATE GlobeNewswire
Mar-04
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) FATE +5.84% GlobeNewswire
Mar-03
Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference FATE -8.67% GlobeNewswire
Feb-26
Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates FATE +5.41% GlobeNewswire
Feb-03
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) FATE -5.69% GlobeNewswire
Jan-05
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) FATE GlobeNewswire
Dec-08
Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs FATE GlobeNewswire
Nov-25
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference FATE GlobeNewswire
Nov-13
Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates FATE GlobeNewswire
Nov-04
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) FATE -8.40% FATE -5.56% GlobeNewswire
Oct-26
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy FATE GlobeNewswire
Oct-14
Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer FATE +7.91% GlobeNewswire
Oct-02
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) FATE GlobeNewswire
Sep-03
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) FATE GlobeNewswire
Aug-25
Fate Therapeutics to Present at Upcoming Investor Conferences FATE -5.22% GlobeNewswire
Aug-12
Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates FATE +20.69% FATE GlobeNewswire
Aug-05
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) FATE GlobeNewswire
Jul-03
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) FATE -5.36% FATE GlobeNewswire
Jun-11
Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress FATE -7.19% GlobeNewswire
May-30
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors FATE -8.33% FATE +7.44% GlobeNewswire
May-28
Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress FATE GlobeNewswire
May-13
Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates FATE -6.54% GlobeNewswire
May-02
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) FATE -10.69% FATE +5.65% GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)